{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T21:48:11Z","timestamp":1789681691078,"version":"4.0.1"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003968","name":"Iran National Science Foundation","doi-asserted-by":"publisher","award":["4026662"],"award-info":[{"award-number":["4026662"]}],"id":[{"id":"10.13039\/501100003968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.semcancer.2025.09.008","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T04:53:46Z","timestamp":1758948826000},"page":"96-107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The complex interplay of lipoprotein(a) and cancer in the era of emerging therapeutics"],"prefix":"10.1016","volume":"116","author":[{"given":"Vanessa","family":"Bianconi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo R.","family":"Mannarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Figorilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Pirro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8656-1444","authenticated-orcid":false,"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semcancer.2025.09.008_bib1","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.phrs.2017.02.001","article-title":"Lipoprotein(a) and inflammation: A dangerous duet leading to endothelial loss of integrity","volume":"119","author":"Pirro","year":"2017","journal-title":"Pharm. Res"},{"key":"10.1016\/j.semcancer.2025.09.008_bib2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.amjcard.2025.02.034","article-title":"Lipoprotein(a) - from biomarker to therapy: a review for the clinician","volume":"245","author":"Jha","year":"2025","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.semcancer.2025.09.008_bib3","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.semcancer.2025.09.008_bib4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s12170-025-00760-1","article-title":"Lipoprotein(a) as a causal risk factor for cardiovascular disease","volume":"19","author":"Doherty","year":"2025","journal-title":"Curr. Cardiovasc Risk Rep."},{"key":"10.1016\/j.semcancer.2025.09.008_bib5","first-page":"69","article-title":"Lipoprotein(a): biology and clinical importance","volume":"25","author":"McCormick","year":"2004","journal-title":"Clin. Biochem. Rev."},{"key":"10.1016\/j.semcancer.2025.09.008_bib6","first-page":"355","article-title":"2024: The year in cardiovascular disease - the year of lipoprotein(a). Research advances and new findings","volume":"21","author":"Sosnowska","year":"2025","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.semcancer.2025.09.008_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104858","article-title":"Apolipoprotein(a), an enigmatic anti-angiogenic glycoprotein in human plasma: A curse or cure?","volume":"158","author":"Kalaivani","year":"2020","journal-title":"Pharm. Res"},{"key":"10.1016\/j.semcancer.2025.09.008_bib8","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.atherosclerosis.2022.04.001","article-title":"Oxidized phospholipid modification of lipoprotein(a): Epidemiology, biochemistry and pathophysiology","volume":"349","author":"Koschinsky","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.semcancer.2025.09.008_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12103543","article-title":"Lipoprotein(a) does not predict thrombotic events and in-hospital outcomes in patients with COVID-19","volume":"12","author":"Bianconi","year":"2023","journal-title":"J. Clin. Med"},{"key":"10.1016\/j.semcancer.2025.09.008_bib10","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1194\/jlr.R083626","article-title":"The role of lipoprotein (a) in chronic kidney disease","volume":"59","author":"Hopewell","year":"2018","journal-title":"J. Lipid Res"},{"key":"10.1016\/j.semcancer.2025.09.008_bib11","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.atherosclerosis.2022.04.016","article-title":"Lipoprotein (a) and diabetes mellitus","volume":"349","author":"Lamina","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.semcancer.2025.09.008_bib12","article-title":"Lipoprotein(a) and risk of cognitive impairment in Black and White Americans: the Reasons for Geographic and Racial Differences in Stroke cohort","volume":"7","author":"Arce Renteria","year":"2023","journal-title":"Res Pr. Thromb. Haemost."},{"key":"10.1016\/j.semcancer.2025.09.008_bib13","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1161\/01.ATV.20.4.1137","article-title":"Major reduction in plasma Lp(a) levels during sepsis and burns","volume":"20","author":"Mooser","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.semcancer.2025.09.008_bib14","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s43556-024-00218-7","article-title":"The functions of apolipoproteins and lipoproteins in health and disease","volume":"5","author":"Ma","year":"2024","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.semcancer.2025.09.008_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25084232","article-title":"Atherosclerosis and the bidirectional relationship between cancer and cardiovascular disease: from bench to bedside-part 1","volume":"25","author":"Gallucci","year":"2024","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.semcancer.2025.09.008_bib16","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.semcancer.2017.11.005","article-title":"Enzymes involved in tumor-driven angiogenesis: A valuable target for anticancer therapy","volume":"56","author":"Ricciuti","year":"2019","journal-title":"Semin Cancer Biol."},{"key":"10.1016\/j.semcancer.2025.09.008_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15174408","article-title":"Association of fibrinolytic potential and risk of mortality in cancer patients","volume":"15","author":"Gois","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.semcancer.2025.09.008_bib18","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ctrv.2007.02.006","article-title":"Lipoprotein[a] and cancer: anti-neoplastic effect besides its cardiovascular potency","volume":"33","author":"Lippi","year":"2007","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.semcancer.2025.09.008_bib19","first-page":"555","article-title":"Lipoprotein(a) in vascular disease, cancer and longevity","volume":"34","author":"Hsieh Wu","year":"2011","journal-title":"Chang Gung Med J."},{"key":"10.1016\/j.semcancer.2025.09.008_bib20","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1194\/jlr.R067314","article-title":"Structure, function, and genetics of lipoprotein (a)","volume":"57","author":"Schmidt","year":"2016","journal-title":"J. Lipid Res"},{"key":"10.1016\/j.semcancer.2025.09.008_bib21","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1006\/bbrc.1998.9116","article-title":"Stimulatory effect of lipoprotein (a) on proliferation of human mesangial cells: role of lipoprotein (a) in renal disease","volume":"249","author":"Morishita","year":"1998","journal-title":"Biochem. Biophys. Res Commun."},{"key":"10.1016\/j.semcancer.2025.09.008_bib22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0021-9150(96)05829-7","article-title":"Lipoprotein(a) induces cell growth in rat peritoneal macrophages through inhibition of transforming growth factor-beta activation","volume":"125","author":"Sato","year":"1996","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.semcancer.2025.09.008_bib23","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0002-9440(10)64366-0","article-title":"Lipoprotein(a) promotes smooth muscle cell proliferation and dedifferentiation in atherosclerotic lesions of human apo(a) transgenic rabbits","volume":"160","author":"Ichikawa","year":"2002","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.semcancer.2025.09.008_bib24","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1161\/01.ATV.21.3.433","article-title":"Impact of apolipoprotein(a) on in vitro angiogenesis","volume":"21","author":"Schulter","year":"2001","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.semcancer.2025.09.008_bib25","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/hep.21149","article-title":"Adeno-associated virus-mediated expression of apolipoprotein (a) kringles suppresses hepatocellular carcinoma growth in mice","volume":"43","author":"Lee","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.semcancer.2025.09.008_bib26","doi-asserted-by":"crossref","first-page":"29000","DOI":"10.1074\/jbc.M301042200","article-title":"Inhibition of angiogenesis and angiogenesis-dependent tumor growth by the cryptic kringle fragments of human apolipoprotein(a)","volume":"278","author":"Kim","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.semcancer.2025.09.008_bib27","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/jgm.638","article-title":"Expression of human apolipoprotein(a) kringles in colon cancer cells suppresses angiogenesis-dependent tumor growth and peritoneal dissemination","volume":"7","author":"Yu","year":"2005","journal-title":"J. Gene Med."},{"key":"10.1016\/j.semcancer.2025.09.008_bib28","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1006\/bbrc.1999.0519","article-title":"Apolipoprotein(a), a link between atherosclerosis and tumor angiogenesis","volume":"257","author":"Trieu","year":"1999","journal-title":"Biochem. Biophys. Res Commun."},{"key":"10.1016\/j.semcancer.2025.09.008_bib29","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.bbrc.2003.11.148","article-title":"Human apolipoprotein(a) kringle V inhibits angiogenesis in vitro and in vivo by interfering with the activation of focal adhesion kinases","volume":"313","author":"Kim","year":"2004","journal-title":"Biochem. Biophys. Res Commun."},{"key":"10.1016\/j.semcancer.2025.09.008_bib30","doi-asserted-by":"crossref","first-page":"21808","DOI":"10.1074\/jbc.M313633200","article-title":"A truncated kringle domain of human apolipoprotein(a) inhibits the activation of extracellular signal-regulated kinase 1 and 2 through a tyrosine phosphatase-dependent pathway","volume":"279","author":"Ahn","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.semcancer.2025.09.008_bib31","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/ijc.24027","article-title":"A novel peptide from human apolipoprotein(a) inhibits angiogenesis and tumor growth by targeting c-Src phosphorylation in VEGF-induced human umbilical endothelial cells","volume":"124","author":"Yi","year":"2009","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.semcancer.2025.09.008_bib32","doi-asserted-by":"crossref","first-page":"895","DOI":"10.3892\/ijo.2016.3597","article-title":"Lipoprotein(a) and vitamin C impair development of breast cancer tumors in Lp(a)+; Gulo-\/- mice","volume":"49","author":"Cha","year":"2016","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.semcancer.2025.09.008_bib33","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1582-4934.2005.tb00356.x","article-title":"Angiogenesis inhibitors found within the haemostasis pathway","volume":"9","author":"Staton","year":"2005","journal-title":"J. Cell Mol. Med"},{"key":"10.1016\/j.semcancer.2025.09.008_bib34","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1177\/1535370219855002","article-title":"Activity of MUC1 cancer antigen-binding plasma anti-alpha-galactoside antibody correlates inversely with size of autologous lipoprotein(a)","volume":"244","author":"John","year":"2019","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.semcancer.2025.09.008_bib35","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1177\/1535370220901493","article-title":"Low reactivity of tumor MUC1-binding natural anti-alpha-galactoside antibody is a risk factor for breast cancer","volume":"245","author":"John","year":"2020","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.semcancer.2025.09.008_bib36","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1023\/A:1026525121027","article-title":"Angiostatin and angiostatin-related proteins","volume":"19","author":"Soff","year":"2000","journal-title":"Cancer Metastas. Rev."},{"key":"10.1016\/j.semcancer.2025.09.008_bib37","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/annonc\/mdj055","article-title":"Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer: a phase II study from Indiana University","volume":"17","author":"Kurup","year":"2006","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.semcancer.2025.09.008_bib38","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0009-3084(94)90147-3","article-title":"Immunochemically detectable lipid-free apo(a) in plasma and in human atherosclerotic lesions","volume":"67-68","author":"Hoff","year":"1994","journal-title":"Chem. Phys. Lipids"},{"issue":"3","key":"10.1016\/j.semcancer.2025.09.008_bib39","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1159\/000045816","article-title":"Elevated plasma free apo(a) levels in hemodialysis patients","volume":"86","author":"Shoji","year":"2000","journal-title":"Nephron"},{"issue":"8","key":"10.1016\/j.semcancer.2025.09.008_bib40","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1161\/hq0801.093654","article-title":"Molecular analysis of apo(a) fragmentation in polygenic hypercholesterolemia: characterization of a new plasma fragment pattern","volume":"21","author":"Gonbert","year":"2001","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.semcancer.2025.09.008_bib41","first-page":"1","article-title":"Lipoprotein(a) in 505 hospitalized patients with various pathological states: correlations with cardiovascular diseases and therapies","volume":"15","author":"Constans","year":"1996","journal-title":"Int. Angiol."},{"key":"10.1016\/j.semcancer.2025.09.008_bib42","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70587","article-title":"Lipid profile, PCSK9, ANGPTL3 and lipoprotein (a) levels in men diagnosed with localized high-grade prostate cancer and men at-risk of prostate cancer","volume":"14","author":"Bergeron","year":"2025","journal-title":"Cancer Med."},{"key":"10.1016\/j.semcancer.2025.09.008_bib43","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/ijc.2910520302","article-title":"Lipoprotein(a) and CA125 levels in the plasma of patients with benign and malignant ovarian disease","volume":"52","author":"Kuesel","year":"1992","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.semcancer.2025.09.008_bib44","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1186\/s12885-022-10120-6","article-title":"Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers","volume":"22","author":"Wong Chong","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.semcancer.2025.09.008_bib45","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1186\/s12876-024-03479-2","article-title":"Blood lipid profiles associated with metastatic sites in advanced gastric cancer","volume":"24","author":"Zhang","year":"2024","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.semcancer.2025.09.008_bib46","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/(SICI)1097-0142(19980715)83:2<379::AID-CNCR24>3.0.CO;2-P","article-title":"Blood lipid profiles in children with acute lymphoblastic leukemia","volume":"83","author":"Halton","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.semcancer.2025.09.008_bib47","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12903-023-02859-6","article-title":"Clinical relevance of serum lipids in the carcinogenesis of oral squamous cell carcinoma","volume":"23","author":"Qian","year":"2023","journal-title":"BMC Oral. Health"},{"key":"10.1016\/j.semcancer.2025.09.008_bib48","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.pcad.2024.08.004","article-title":"The prevalence, patients' characteristics, and hyper-Lp(a)-emia risk factors in the Polish population. The first results from the PMMHRI-Lp(a) Registry","volume":"86","author":"Sosnowska","year":"2024","journal-title":"Prog. Cardiovasc. Dis."},{"key":"10.1016\/j.semcancer.2025.09.008_bib49","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/ijc.2910430212","article-title":"Elevated apolipoprotein(a) levels in cancer patients","volume":"43","author":"Wright","year":"1989","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.semcancer.2025.09.008_bib50","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3109\/00365519409088568","article-title":"The behaviour of lipoprotein(a) in patients with various diseases","volume":"54","author":"Van Wersch","year":"1994","journal-title":"Scand. J. Clin. Lab Invest."},{"key":"10.1016\/j.semcancer.2025.09.008_bib51","doi-asserted-by":"crossref","first-page":"1181508","DOI":"10.3389\/fonc.2023.1181508","article-title":"Relationship between lipoprotein(a) and colorectal cancer among inpatients: a retrospective study","volume":"13","author":"Wang","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.semcancer.2025.09.008_bib52","first-page":"133","article-title":"Elevated serum Lp(a) levels in the early and advanced stages of breast cancer","volume":"14","author":"Kokoglu","year":"1994","journal-title":"Cancer Biochem. Biophys."},{"key":"10.1016\/j.semcancer.2025.09.008_bib53","article-title":"Hyperlipoproteinemia (a) is associated with breast cancer in a Han Chinese population","volume":"99","author":"Xu","year":"2020","journal-title":"Medicine"},{"key":"10.1016\/j.semcancer.2025.09.008_bib54","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s40001-022-00784-y","article-title":"The association between serum lipid levels and histological type of breast cancer","volume":"27","author":"Wang","year":"2022","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.semcancer.2025.09.008_bib55","doi-asserted-by":"crossref","first-page":"9483935","DOI":"10.1155\/2019\/9483935","article-title":"High lipoprotein(a) level is independently associated with adverse clinicopathological features in patients with prostate cancer","volume":"2019","author":"Wang","year":"2019","journal-title":"Dis. Markers"},{"key":"10.1016\/j.semcancer.2025.09.008_bib56","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1515\/CCLM.2009.094","article-title":"Lipoprotein(a) level and its association with tumor stage in male patients with primary lung cancer","volume":"47","author":"Yang","year":"2009","journal-title":"Clin. Chem. Lab Med."},{"key":"10.1016\/j.semcancer.2025.09.008_bib57","doi-asserted-by":"crossref","first-page":"298","DOI":"10.21037\/apm.2020.01.16","article-title":"Endostar improved efficacy of concurrent chemoradiotherapy with vinorelbine plus carboplatin in locally advanced lung squamous cell carcinoma patients with high serum Lp(a) concentration","volume":"9","author":"Xu","year":"2020","journal-title":"Ann. Palliat. Med."},{"key":"10.1016\/j.semcancer.2025.09.008_bib58","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7331","article-title":"Association of preoperative elevated lipoprotein (a) with poor survival in patients with biliary tract cancers","volume":"13","author":"Fan","year":"2024","journal-title":"Cancer Med."},{"key":"10.1016\/j.semcancer.2025.09.008_bib59","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1476-511X-5-4","article-title":"Influence of liver cancer on lipid and lipoprotein metabolism","volume":"5","author":"Jiang","year":"2006","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.semcancer.2025.09.008_bib60","first-page":"301","article-title":"Lipoprotein (a) behaviour in patients with hepatocellular carcinoma","volume":"92","author":"Motta","year":"2001","journal-title":"Minerva Med."},{"key":"10.1016\/j.semcancer.2025.09.008_bib61","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1476-511X-7-25","article-title":"Increased plasma apoM levels in the patients suffered from hepatocellular carcinoma and other chronic liver diseases","volume":"7","author":"Jiang","year":"2008","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.semcancer.2025.09.008_bib62","doi-asserted-by":"crossref","first-page":"71","DOI":"10.4103\/0971-5851.89775","article-title":"Lipoprotein(a) as a potential marker of residual liver function in hepatocellular carcinoma","volume":"32","author":"Uccello","year":"2011","journal-title":"Indian J. Med. Paediatr. Oncol."},{"key":"10.1016\/j.semcancer.2025.09.008_bib63","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0009-8981(97)06533-9","article-title":"Lipoprotein (a) serum levels in patients with hepatocarcinoma","volume":"262","author":"Basili","year":"1997","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.semcancer.2025.09.008_bib64","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s40520-016-0653-z","article-title":"Lipoprotein(a) in patients with hepatocellular carcinoma and portal vein thrombosis","volume":"29","author":"Malaguarnera","year":"2017","journal-title":"Aging Clin. Exp. Res."},{"key":"10.1016\/j.semcancer.2025.09.008_bib65","doi-asserted-by":"crossref","first-page":"5917","DOI":"10.2147\/OTT.S164273","article-title":"Lipoprotein (a): a promising prognostic biomarker in patients with hepatocellular carcinoma after curative resection","volume":"11","author":"Gao","year":"2018","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.semcancer.2025.09.008_bib66","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.canep.2014.07.013","article-title":"Significant association between hypolipoproteinemia(a) and lifetime risk of cancer: an autopsy study from a community-based Geriatric Hospital","volume":"38","author":"Mieno","year":"2014","journal-title":"Cancer Epidemiol."},{"key":"10.1016\/j.semcancer.2025.09.008_bib67","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/CEJ.0b013e328359cba7","article-title":"Lipoprotein(a) plasma levels and the risk of cancer: the PRIME study","volume":"22","author":"Marrer","year":"2013","journal-title":"Eur. J. Cancer Prev."},{"key":"10.1016\/j.semcancer.2025.09.008_bib68","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.metabol.2019.01.007","article-title":"Association between obesity and biomarkers of inflammation and metabolism with cancer mortality in a prospective cohort study","volume":"94","author":"Dibaba","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/j.semcancer.2025.09.008_bib69","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Emerging Risk Factors C","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.semcancer.2025.09.008_bib70","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/ijc.34795","article-title":"Circulating levels of biomarkers and risk of ductal carcinoma in situ of the breast in the UK Biobank study","volume":"154","author":"Peila","year":"2024","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.semcancer.2025.09.008_bib71","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/eurjpc\/zwac271","article-title":"Lipoprotein(a)-related cardiovascular and all-cause mortalities in Korean adults","volume":"30","author":"Kim","year":"2023","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.semcancer.2025.09.008_bib72","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1186\/s12889-024-19443-4","article-title":"Association between lipoprotein(a), fibrinogen and their combination with all-cause, cardiovascular disease and cancer-related mortality: findings from the NHANES","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Public Health"},{"key":"10.1016\/j.semcancer.2025.09.008_bib73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/CLEP.S437456","article-title":"Inflammation-Dependent Association of Lipoprotein (a) with Cardiovascular and Cancer Mortality","volume":"16","author":"Zhang","year":"2024","journal-title":"Clin. Epidemiol."},{"key":"10.1016\/j.semcancer.2025.09.008_bib74","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s12916-017-0976-4","article-title":"Blood lipids and lipoproteins in relation to incidence and mortality risks for CVD and cancer in the prospective EPIC-Heidelberg cohort","volume":"15","author":"Katzke","year":"2017","journal-title":"BMC Med."},{"key":"10.1016\/j.semcancer.2025.09.008_bib75","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0031954","article-title":"Low lipoprotein(a) concentration is associated with cancer and all-cause deaths: a population-based cohort study (the JMS cohort study)","volume":"7","author":"Sawabe","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.semcancer.2025.09.008_bib76","doi-asserted-by":"crossref","first-page":"6465","DOI":"10.2147\/IJGM.S501401","article-title":"Pretreatment Lipoprotein(a) as a biomarker for EGFR mutation and prognosis in lung adenocarcinoma","volume":"17","author":"Liu","year":"2024","journal-title":"Int J. Gen. Med"},{"key":"10.1016\/j.semcancer.2025.09.008_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2024.100528","article-title":"Causal association of blood lipids with all-cause and cause-specific mortality risk: a Mendelian randomization study","volume":"65","author":"Lu","year":"2024","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.semcancer.2025.09.008_bib78","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/eurheartj\/ehaa1085","article-title":"Low lipoprotein(a) levels and risk of disease in a large, contemporary, general population study","volume":"42","author":"Langsted","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.semcancer.2025.09.008_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2023.102395","article-title":"Lack of significant associations between single nucleotide polymorphisms in LPAL2-LPA genetic region and all cancer incidence and mortality in Japanese population: The Japan public health center-based prospective study","volume":"85","author":"Mieno","year":"2023","journal-title":"Cancer Epidemiol."},{"key":"10.1016\/j.semcancer.2025.09.008_bib80","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1016\/j.jacc.2016.10.033","article-title":"Phenotypic characterization of genetically lowered human lipoprotein(a) levels","volume":"68","author":"Emdin","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.semcancer.2025.09.008_bib81","first-page":"3629","article-title":"Genetic association of cardiovascular disease related biomarkers with the overall survival of hepatocellular carcinoma: a mendelian randomization analysis","volume":"13","author":"Wen","year":"2023","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.semcancer.2025.09.008_bib82","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/01635581.2023.2294521","article-title":"Blood lipid metabolic profiles and causal links to site-specific cancer risks: a mendelian randomization study","volume":"76","author":"Chen","year":"2024","journal-title":"Nutr. Cancer"},{"key":"10.1016\/j.semcancer.2025.09.008_bib83","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s12672-024-01493-0","article-title":"Identifying causal relationships between 35 blood and urine biomarkers and urologic cancers: MR-meta combined with Bayesian colocalization Mendelian randomization analysis","volume":"15","author":"An","year":"2024","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.semcancer.2025.09.008_bib84","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003859","article-title":"The relationship between lipoprotein A and other lipids with prostate cancer risk: a multivariable mendelian randomisation study","volume":"19","author":"Ioannidou","year":"2022","journal-title":"PLoS Med."},{"key":"10.1016\/j.semcancer.2025.09.008_bib85","doi-asserted-by":"crossref","first-page":"814","DOI":"10.3389\/fgene.2020.00814","article-title":"Integrated bioinformatics analysis reveals key candidate genes and pathways associated with clinical outcome in hepatocellular carcinoma","volume":"11","author":"Li","year":"2020","journal-title":"Front Genet"},{"key":"10.1016\/j.semcancer.2025.09.008_bib86","doi-asserted-by":"crossref","DOI":"10.1177\/15330338211058352","article-title":"Colorectal cancer detected by machine learning models using conventional laboratory test data","volume":"20","author":"Li","year":"2021","journal-title":"Technol. Cancer Res Treat."},{"key":"10.1016\/j.semcancer.2025.09.008_bib87","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1186\/s12905-024-03264-z","article-title":"Development and validation of an artificial intelligence model for predicting de novo distant bone metastasis in breast cancer: a dual-center study","volume":"24","author":"Zhang","year":"2024","journal-title":"BMC Womens. Health"},{"key":"10.1016\/j.semcancer.2025.09.008_bib88","doi-asserted-by":"crossref","first-page":"15561","DOI":"10.1038\/s41598-024-66658-x","article-title":"AI models predicting breast cancer distant metastasis using LightGBM with clinical blood markers and ultrasound maximum diameter","volume":"14","author":"Tan","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.semcancer.2025.09.008_bib89","doi-asserted-by":"crossref","first-page":"7879508","DOI":"10.1155\/2021\/7879508","article-title":"A novel predictive nomogram including serum lipoprotein a level for nonsentinel lymph node metastases in Chinese breast cancer patients with positive sentinel lymph node metastases","volume":"2021","author":"Fang","year":"2021","journal-title":"Dis. Markers"},{"key":"10.1016\/j.semcancer.2025.09.008_bib90","article-title":"Using topic modeling via non-negative matrix factorization to identify relationships between genetic variants and disease phenotypes: A case study of Lipoprotein(a) (LPA)","volume":"14","author":"Zhao","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.semcancer.2025.09.008_bib91","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.atherosclerosis.2022.04.006","article-title":"Non-genetic influences on lipoprotein(a) concentrations","volume":"349","author":"Enkhmaa","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.semcancer.2025.09.008_bib92","doi-asserted-by":"crossref","DOI":"10.1007\/s12020-024-04128-0","article-title":"The impact of tamoxifen on apolipoproteins and lipoprotein(a) levels: an updated meta-analysis of randomized controlled trials","author":"Jiang","year":"2025","journal-title":"Endocrine"},{"key":"10.1016\/j.semcancer.2025.09.008_bib93","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s40265-017-0767-4","article-title":"The effects of tamoxifen on plasma lipoprotein(a) concentrations: systematic review and meta-analysis","volume":"77","author":"Sahebkar","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.semcancer.2025.09.008_bib94","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/0026-0495(94)90190-2","article-title":"Tamoxifen decreases lipoprotein (a) in patients with breast cancer","volume":"43","author":"Shewmon","year":"1994","journal-title":"Metabolism"},{"key":"10.1016\/j.semcancer.2025.09.008_bib95","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/BF01806815","article-title":"Effects of tamoxifen on serum lipid and apolipoprotein levels in postmenopausal patients with breast cancer","volume":"40","author":"Morales","year":"1996","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.semcancer.2025.09.008_bib96","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-004-4384-z","article-title":"Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer","volume":"88","author":"Kusama","year":"2004","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.semcancer.2025.09.008_bib97","first-page":"2725","article-title":"The beneficial effect of tamoxifen on serum lipoprotein-A levels: an additional anti-atherogenic property","volume":"16","author":"Elisaf","year":"1996","journal-title":"Anticancer Res."},{"key":"10.1016\/j.semcancer.2025.09.008_bib98","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000048256","article-title":"Are the effects of tamoxifen on the serum lipid profile modified by apolipoprotein E phenotypes?","volume":"62","author":"Liberopoulos","year":"2002","journal-title":"Oncology"},{"key":"10.1016\/j.semcancer.2025.09.008_bib99","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1200\/JCO.1996.14.2.429","article-title":"Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer","volume":"14","author":"Saarto","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2025.09.008_bib100","first-page":"3337","article-title":"Effect of aromatase inhibitors on lipid metabolism, inflammatory response and antioxidant balance in patients with breast carcinoma","volume":"29","author":"Melichar","year":"2009","journal-title":"Anticancer Res"},{"key":"10.1016\/j.semcancer.2025.09.008_bib101","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/annonc\/mdi158","article-title":"The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L)","volume":"16","author":"Wasan","year":"2005","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.semcancer.2025.09.008_bib102","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/S0959-8049(01)00155-1","article-title":"Effect of letrozole on the lipid profile in postmenopausal women with breast cancer","volume":"37","author":"Elisaf","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.semcancer.2025.09.008_bib103","first-page":"2508","article-title":"Treatment of prostate cancer with gonadotropin-releasing hormone analogue: effect on lipoprotein[a]","volume":"81","author":"Arrer","year":"1996","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2025.09.008_bib104","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1507\/endocrj.40.507","article-title":"Reduction of serum lipoprotein (a) by estrogen in men with prostatic cancer","volume":"40","author":"Hiraga","year":"1993","journal-title":"Endocr. J."},{"key":"10.1016\/j.semcancer.2025.09.008_bib105","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1093\/clinchem\/42.8.1176","article-title":"Effects of androgen suppression by gonadotropin-releasing hormone agonist and flutamide on lipid metabolism in men with prostate cancer: focus on lipoprotein(a)","volume":"42","author":"Denti","year":"1996","journal-title":"Clin. Chem."},{"key":"10.1016\/j.semcancer.2025.09.008_bib106","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s12032-010-9593-1","article-title":"Intima-media thickness, myocardial perfusion and laboratory risk factors of atherosclerosis in patients with breast cancer treated with anthracycline-based chemotherapy","volume":"28","author":"Kalabova","year":"2011","journal-title":"Med. Oncol."},{"key":"10.1016\/j.semcancer.2025.09.008_bib107","first-page":"287","article-title":"Glucose and lipid metabolism in patients with advanced pancreatic cancer receiving palliative chemotherapy","volume":"33","author":"Zeiss","year":"2013","journal-title":"Anticancer Res."},{"key":"10.1016\/j.semcancer.2025.09.008_bib108","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/BF00180286","article-title":"Elevated lipoprotein(a) levels in patients with acute myeloblastic leukaemia decrease after successful chemotherapeutic treatment","volume":"70","author":"Niendorf","year":"1992","journal-title":"Clin. Invest."},{"key":"10.1016\/j.semcancer.2025.09.008_bib109","doi-asserted-by":"crossref","first-page":"8397","DOI":"10.2147\/CMAR.S253397","article-title":"Effects of chemotherapy on serum lipids in chinese postoperative breast cancer patients","volume":"12","author":"Lu","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.semcancer.2025.09.008_bib110","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1006\/bbrc.1996.1547","article-title":"An in vitro system for identifying agents capable of changing serum lipoprotein(a) concentration by regulating the transcriptional activity of the apolipoprotein(a) gene promoter","volume":"227","author":"Azuma","year":"1996","journal-title":"Biochem. Biophys. Res Commun."},{"key":"10.1016\/j.semcancer.2025.09.008_bib111","first-page":"4453","article-title":"Effects of chemotherapy-induced castration on serum lipids and apoproteins in premenopausal women with node-positive breast cancer","volume":"81","author":"Saarto","year":"1996","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.semcancer.2025.09.008_bib112","doi-asserted-by":"crossref","DOI":"10.1111\/eci.14254","article-title":"New insights into the therapeutic options to lower lipoprotein(a)","volume":"54","author":"Baragetti","year":"2024","journal-title":"Eur. J. Clin. Invest"},{"key":"10.1016\/j.semcancer.2025.09.008_bib113","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00395-024-01080-y","article-title":"Cardio-oncology: chances and challenges","volume":"120","author":"Vi\u00f1as-Mendieta","year":"2025","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.semcancer.2025.09.008_bib114","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.scib.2025.01.016","article-title":"Enhancing panvascular medicine: unveiling the nexus of pan-cardio-oncology and expanding therapeutic frontiers","volume":"70","author":"Hu","year":"2025","journal-title":"Sci. Bull."}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X25001245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X25001245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T10:38:10Z","timestamp":1773139090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X25001245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":114,"alternative-id":["S1044579X25001245"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2025.09.008","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The complex interplay of lipoprotein(a) and cancer in the era of emerging therapeutics","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2025.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}